Glucose Variation Doesn't Affect Microvascular Complications

Share this content:
Glucose Variation Doesn't Affect Microvascular Complications
Glucose Variation Doesn't Affect Microvascular Complications

TUESDAY, April 18, 2017 (HealthDay News) -- Measures of glycemic variability in type 1 diabetes, based on complete quarterly 7-point glucose profiles, fail to provide evidence that glycemic variability contributes to the risk of development or progression of microvascular complications beyond the influence of mean glucose levels, according to a study published online April 12 in Diabetes Care.

John M. Lachin, Sc.D., from George Washington University in Rockville, Md., and colleagues utilized data from the Diabetes Control and Complications Trial to assess the association of glucose variability within and between quarterly 7-point glucose profiles and the development and progression of retinopathy, nephropathy, and cardiovascular autonomic neuropathy.

The researchers found that adjusting for mean blood glucose, no measure of within-day variability was associated with any outcome. There was a significant association between the longitudinal mean M-value (over time) and microalbuminuria, when adjusted for the longitudinal mean blood glucose and corrected for multiple tests using the Holm procedure.

"Overall, within-day glycemic variability, as determined from quarterly glucose profiles, does not play an apparent role in the development of microvascular complications beyond the influence of the mean glucose," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Higher Fish Intake Appears to Reduce RA Symptoms

Higher Fish Intake Appears to Reduce RA Symptoms

Researchers suggest most varieties of fish may play a role in controlling symptoms

Longer Survival for Midostaurin  Chemotherapy in AML With FLT3

Longer Survival for Midostaurin + Chemotherapy in AML ...

Prolonged overall, event-free survival for patients with acute myeloid leukemia, FLT3 mutation

HIV Testing Inadequate in Young Men Who Have Sex With Men

HIV Testing Inadequate in Young Men Who Have ...

Only 28 percent of young MSM have HIV testing, though they account for 83 percent of new diagnoses

is free, fast, and customized just for you!

Already a member?

Sign In Now »